title: [Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN].
abstract: Diabetes increases the risk of both microvascular and macrovascular complications. Although reducing plasma glucose levels to recommended targets decreases the risk of microvascular outcomes, the effects of anti-diabetic drugs on macrovascular complications and cardiovascular death are of concern. In fact, it has been suggested that some anti-diabetic agents could even be harmful for cardiovascular outcomes. In this context, several health care regulatory agencies have established the need for performing clinical trials specifically designed to assess the cardiovascular safety of anti-diabetic drugs. The results of 2 clinical trials have recently been published that provide important information on the cardiovascular safety of dipeptidyl peptidase 4 (DPP-4) inhibitors. The aim of this document was to review the available evidence on the cardiovascular safety of non-insulin anti-diabetic drugs and provide practical recommendations on their use in this context.
authors.affiliation: Centro de Salud de Vallobín - La Florida, Oviedo, Grupo de Trabajo de Hipertensión Arterial de SEMERGEN, Coordinador del Área Cardiovascular de SEMERGEN. Electronic address: maprietodiaz@telefonica.net.
authors.forename: M Á
authors.initials: MÁ
authors.lastname: Prieto
authors.affiliation: Centro de Salud La Puebla de Montalbán (Toledo), Miembro Grupo de Trabajo Diabetes-SEMERGEN, Vocal Junta Nacional SEMERGEN, Responsable Grupos de Trabajo.
authors.forename: J M
authors.initials: JM
authors.lastname: Comas Samper
authors.affiliation: Servicio de Cardiología. Hospital Universitario La Paz, Madrid, Colaborador Grupo de Trabajo de Hipertensión Arterial SEMERGEN.
authors.forename: C
authors.initials: C
authors.lastname: Escobar Cervantes
authors.affiliation: C.S. de Torrent II, Presidente de SEMERGEN Comunidad Valenciana, Miembro del Grupo de Diabetes de SEMERGEN.
authors.forename: V
authors.initials: V
authors.lastname: Gasull Molinera
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents
keywords: Agonistas receptores GLP-1; Alpha-glucosidase inhibitors; Anti-diabetic drugs; Antidiabéticos; Biguanidas; Biguanides; Cardiovascular safety; DPP-4 inhibitors; Diabetes; EXAMINE; GLP-1 receptor agonists; Inhibidores DPP-4; Inhibidores SGLT2; Inhibidores de la alfa glucosidasa; Meglitinidas; Meglitinides; SAVOR-TIMI 53; SGLT2 inhibitors; Seguridad cardiovascular; Sulfonilureas; Sulfonylureas; Thiazolidinediones; Tiazolidindionas